Clinical trial NCT04846686: Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.
Official title: Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Preeclampsia
Keywords: Preeclampsia
EG-VEGF
Prokineticin
cesarean
placenta pathological examination
pregnancy
PROK1 receptor
PROKR2 receptor
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
Collaborators: name: Commissariat A L'energie Atomique
First posted: 2021-04-15
Enrollment: 35
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital.

Brief summary: The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation results from an imbalance of angiogenic factors.

A new angiogenic factor EG-VEGF (Endocrine Gland- Derived Vascular Endothelial Growth Factor) also known as Prokineticin 1 (PROK1) appears to be emerging in the pathophysiology of PE. EG-VEGF is a circulating factor which belongs to the family of prokinetics. Dr Alfaidy's MAB2 team at the Cancer and Infections Biology Laboratory (U1292 Biosanté INSERM / UGA / CEA, CEA Grenoble) demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia. EG -VEGF is directly involved in the development of Pre-Eclampsia. Few studies have evaluated the expression of EG-VEGF in the human placenta.


Eligibility criteria: Inclusion Criteria:

* All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital.
* For the pre-eclampsia group: patient with a diagnosis of pre-eclampsia
* For the control group: patient who had a normal pregnancy

Exclusion Criteria:

* Patient who gave birth naturally
* Underage patients or under guardianship
* Patients who do not speak or read French
* Childbirth under X

Primary outcomes:
measure: Immuno-localization of EG-VEGF staining (ImageJ®) by immunohistochemistry
timeFrame: At delivery
measure: Quantification of EG-VEGF staining (ImageJ®) by immunohistochemistry
timeFrame: At delivery
Secondary outcomes:
measure: Immuno-localization of the staining of PROKR1 (ImageJ®) by immunohistochemistry
timeFrame: At delivery
measure: Quantification of the staining of PROKR1 (ImageJ®) by immunohistochemistry
timeFrame: At delivery
measure: Immuno-localization of the staining of PROKR2 (ImageJ®) by immunohistochemistry
timeFrame: At delivery
measure: Quantification of the staining of PROKR2 (ImageJ®) by immunohistochemistry Measure by placenta pathological examination (immunohistochemistry technical).
timeFrame: At delivery
measure: Presence of at least one chronic maternal pathologies describe below
timeFrame: At delivery
measure: Obstetric history
timeFrame: At delivery
measure: Presence of an anticoagulant treatment
timeFrame: At delivery
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: Chu Saint-Etienne
Study officials:
affiliation: CHU SAINT-ETIENNE
name: Tiphaine BARJAT, MD
role: PRINCIPAL_INVESTIGATOR
References: